Mosaic ImmunoEngineering (OTCMKTS:CPMV) & Cullinan Therapeutics (NASDAQ:CGEM) Head-To-Head Survey

Mosaic ImmunoEngineering (OTCMKTS:CPMV) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Volatility & Risk

Mosaic ImmunoEngineering has a beta of -0.92, suggesting that its share price is 192% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500.

Valuation and Earnings

This table compares Mosaic ImmunoEngineering and Cullinan Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mosaic ImmunoEngineering	N/A	N/A	-$690,000.00	($0.09)	-7.49
Cullinan Therapeutics	N/A	N/A	-$219.88 million	($3.36)	-5.14

Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mosaic ImmunoEngineering and Cullinan Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mosaic ImmunoEngineering	N/A	N/A	-1,908.81%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Institutional and Insider Ownership

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 81.0% of Mosaic ImmunoEngineering shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Mosaic ImmunoEngineering and Cullinan Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mosaic ImmunoEngineering	0	0	0	0	0.00
Cullinan Therapeutics	1	1	6	0	2.62

Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 85.19%. Given Cullinan Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Mosaic ImmunoEngineering.

Summary

Cullinan Therapeutics beats Mosaic ImmunoEngineering on 7 of the 11 factors compared between the two stocks.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.